All News
Updated 2018 EULAR Recommendations for the Diagnosis of Gout
The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.
Read ArticleExcess Non-CV Mortality Persists in Gout
Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.
Read ArticleDespite Gout Numbers and Flares, Allopurinol is Underutilized
A population-based survey from South Australia shows that gout flares are common in the community and have a significant effect on health-related quality of life (HRQoL), yet there is significant undertreatment of gout, even in those on current allopurinol.
Read ArticleRheumNow Podcast – Rituximab Monitoring (5.31.19)
Dr. Jack Cush presents the news and best of rheumatology and medicine from the past week on RheumNow.com
Read ArticleRheumNow Podcast – Richer or Poorer (5.17.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleCoexistent Gout Increases Risk in Rheumatoid Arthritis
It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.
Less Structural Damage with T2T in Gout
A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.
Read ArticleRheumNow Podcast – Periodontitis in RA Relatives (5.10.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleCDC: One in Four US Adults have Arthritis
MMWR reports that in 2017, one in four US adults have arthritis (range from 22.8% to 34.6%), with higher rates in Appalachia and Lower Mississippi Valley regions. Of those with arthritis, 31% reported to have "severe arthritis".
Read ArticleNonadherence is Costly for Patients in Pain
A comparative cohort study of patients with osteoarthritis (OA), gout, diabetic peripheral neuropathy (pDPN), post-herpetic neuralgia (PHN), and fibromyalgia (FM) shows that nonadherence to pain medications is high and leads to greater overall health care resource utilization and costs.
Read ArticleIdeal Outcomes are Seldom Achieved in Gout
Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) 6 mg/dL and remission are rare, especially for those with severe gout.
Read ArticleOmega-3 Rich Fish Lowers Gout Flares
Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.
Read ArticleRheumNow Podcast – Eat Your Veggies (4.19.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read ArticleRheumNow Podcast – A Tofa Two-fer (4.12.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com
Read ArticleChronic Kidney Disease Augments Gout Risks
A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.
Read ArticleRheumNow Podcast – Loretta Lynn Arthritis (3.29.19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read ArticleIronwood Retreats from the US Gout Market
Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019.
Read ArticleRheumNow Podcast – Scleroderma and the Lung (3.1.19)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read ArticleAllopurinol Reduces Cardiovascular Outcomes in Diabetes
A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.
Read ArticleFDA Slaps a Boxed Warning on Febuxostat for CV Risk
The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.
Read Article